Key Segmentation
By Indication
-
Chronic Kidney Disease
-
Type 2 Diabetes
-
Cardiovascular
-
Others
By Drug
-
Jardiance
-
Inpefa
-
Farxiga
-
Invokana
-
Qtern
-
Others
By Distribution Channel
-
Retail Pharmacies
-
Hospital Pharmacies
-
Online Pharmacies
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Jardiance (Empagliflozin) dominated with a 51% share of the global diabetes treatment market in 2024.
North America dominated the SGLT2 Inhibitors Market in 2024 with a 41% market share, while Asia Pacific is the fastest-growing region.
The SGLT2 Inhibitors Market was valued at USD 18.14 Billion in 2025.
The SGLT2 Inhibitors Market is expected to grow at a CAGR of 7.33% from 2026 to 2035.
The rising global burden of type 2 diabetes and cardiovascular disease, combined with expanding clinical guideline support for SGLT2 inhibitors as first-line therapy.